Consistently, fresh human WBCs cultured on HER2-coated plates in the absence of cancer cells failed to produce type III IFNs in response to HER2-ADC treatment, despite significant levels of CXCL10 production (Fig. 5e). This evidence concerns the gene ERBB2 and cancer.